Related Experiment Video
Updated: May 12, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
Ryan K Shields1, Emre Yücel2, Vladimir Turzhitsky2
1Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA.
Abstract:
We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understanding of real-world indications and outcomes of imipenem/cilastatin/relebactam use.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
09:07Author Spotlight: Accelerating Diagnostic Accuracy with Direct Identification of Gram-Negatives from Blood Culture Bottles
Published on: May 24, 2024
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Antimicrobial Effectiveness
Automated Microbial Diagnostics
Clinical Significance of Antibiotic Resistance